Abstract 1591P
Background
Novel therapies are transforming cancer care. We have previously shown the substantial rise in the number of new oncology treatments approved in the UK over the past decades. However, UK drug approval has changed substantially following Brexit and faced significant challenges during the COVID-19 pandemic. It is unknown how these factors have affected drug approvals and costs.
Methods
The UK core prescribing book is the British National Formulary (BNF) listing all newly approved drugs. We analysed new therapy additions over a 5-year period, collecting data on classification, indication and median treatment duration. To appreciate costs, we calculated the price per treatment and equated this to the UK GDP per capita.
Results
Between 2020-24, 45 new cancer therapies were approved in the UK, comparing favourably with the previous 5-years, when 46 therapies were approved. The past 10-years (2015-24) has seen 91 new cancer therapies approved; a 78.4% increase compared to the previous 10-years (2005-2014). The past 5-years has witnessed continued transition away from cytotoxic chemotherapy (CC) to targeted therapies. In 2005-09 a third of new therapies were CC drugs, compared to only 6.7% in 2020-24. The majority of new approvals over the last 5-years were kinase inhibitors, accounting for 40% (N=18), followed closely by monoclonal antibodies at 35.6% (N=16). The average median duration of treatment is 438 days, increasing substantially from 318 days in 2015-19 and 263 days in 2010-14. The average monthly treatment cost between 2020-24 is £8286.50, increasing from £5937.43 in 2015-19 and £4090.52 in 2010-14. This equates to a 102.6% growth over 15 years. The average total treatment cost in 2020-24 is £119,325.54, almost double compared to 2015-19 (£62,343). This is equivalent to 361.6% of the UK GDP per capita.
Conclusions
Despite Brexit and the COVID-19 pandemic, the UK has maintained a consistent number of new oncology approvals. A transition away from CC towards targeted therapies is fuelling precision oncology. However, as the median duration of treatment and average cost of new therapies continues to rise they pose ongoing significant challenges.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
G. Majhail.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10